Human CD4- invariant NKT lymphocytes regulate graft versus host disease.
Fiche publication
Date publication
janvier 2018
Journal
Oncoimmunology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick, Pr RUBIO Marie Thérèse , Dr D'AVENI-PINEY Maud
Tous les auteurs :
Coman T, Rossignol J, D'Aveni M, Fabiani B, Dussiot M, Rignault R, Babdor J, Bouillé M, Herbelin A, Coté F, Moura IC, Hermine O, Rubio MT
Lien Pubmed
Résumé
Despite increasing evidence for a protective role of invariant (i) NKT cells in the control of graft-versus-host disease (GVHD), the mechanisms underpinning regulation of the allogeneic immune response in humans are not known. In this study, we evaluated the distinct effects of human expanded and flow-sorted human CD4 and CD4 iNKT subsets on human T cell activation in a pre-clinical humanized NSG mouse model of xenogeneic GVHD. We demonstrate that human CD4 but not CD4 iNKT cells could control xenogeneic GVHD, allowing significantly prolonged overall survival and reduced pathological GVHD scores without impairing human T cell engraftment. Human CD4 iNKT cells reduced the activation of human T cells and their Th1 and Th17 differentiation . CD4 and CD4 iNKT cells had distinct effects upon DC maturation and survival. Compared to their CD4 counterparts, in co-culture experiments , human CD4 iNKT cells had a higher ability to make contacts and degranulate in the presence of mouse bone marrow-derived DCs, inducing their apoptosis. we observed that infusion of PBMC and CD4 iNKT cells was associated with decreased numbers of splenic mouse CD11c DCs. Similar differential effects of the iNKT cell subsets were observed on the maturation and in the induction of apoptosis of human monocyte-derived dendritic cells . These results highlight the increased immunosuppressive functions of CD4 CD4 human iNKT cells in the context of alloreactivity, and provide a rationale for CD4 iNKT selective expansion or transfer to prevent GVHD in clinical trials.
Mots clés
Allogeneic stem cell transplantation, NSG mice, dendritic cells, graft-versus-host disease, human invariant NKT cells, immunoregulation
Référence
Oncoimmunology. 2018 ;7(11):e1470735